Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1
Open Access
- 2 December 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 42-44
Abstract
Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep, resulting from the loss of hypothalamic neurons that produce orexin. Current therapies, including stimulants, antidepressants, and sodium oxybate, primarily offer symptomatic relief without addressing the underlying orexin deficiency and often have safety or adherence limitations. Orexin receptor 2 (OX2R) agonists represent a novel therapeutic strategy aimed at restoring physiological wakefulness by directly targeting the core neurochemical deficit. TAK-994, the first oral OX2R agonist, demonstrated remarkable efficacy in reducing cataplexy and improving wakefulness but was discontinued due to dose-dependent hepatotoxicity. TAK-861 (oveporexton), a next-generation OX2R agonist with improved structural properties, has shown encouraging Phase 2 results with comparable efficacy and a favorable safety profile, including minimal hepatic effects and once-daily dosing convenience. If validated in large-scale Phase 3 studies, TAK-861 could become the first disease-modifying therapy for NT1, representing a paradigm shift from symptomatic management to mechanism-based treatment. The ongoing development of OX2R agonists highlights a promising frontier in precision sleep medicine, offering renewed hope for patients by targeting orexin restoration.Keywords
This publication has 13 references indexed in Scilit:
- Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1New England Journal of Medicine, 2025
- 0624 A Mass Spectrometry Method Evaluating Orexin Metabolites Suggest Abnormalities in Hypersomnias of Central OriginSLEEP, 2024
- Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1New England Journal of Medicine, 2023
- Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patientsProceedings of the National Academy of Sciences, 2022
- Agonists and antagonists of the orexinergic system: therapeutic molecules of the future - a narrative reviewBIOMEDICA, 2022
- NarcolepsyJournal of Sleep Research, 2022
- Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 AgonistsJournal of Medicinal Chemistry, 2015
- Selective orexin receptor antagonistsBioorganic & Medicinal Chemistry Letters, 2013
- Therapies for narcolepsy with or without cataplexy: evidence-based reviewCurrent Opinion in Neurology, 2007
- The Hypocretin/Orexin SystemJournal of the Royal Society of Medicine, 2002